<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920216</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00014-47</org_study_id>
    <nct_id>NCT02920216</nct_id>
  </id_info>
  <brief_title>Interest of Fluorescence in Salvage Surgery for Recurrence of Head and Neck Cancer in Irradiated Area</brief_title>
  <acronym>SALVADS-Fluo</acronym>
  <official_title>Pilot Study of Evaluation of the Interest of Fluorescence in Salvage Surgery for Recurrence of Head and Neck Cancer in Irradiated Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of Head and Neck Squamous cell carcinoma often combines chemoradiotherapy when&#xD;
      organ has to be preserved or when surgery is not indicated. The loco-regional failure is&#xD;
      about 30%. Then salvage surgery is the only chance for patients to survive but the overall&#xD;
      survival rate is only 29% at 24 months. This prognostic is bad because of poor local control&#xD;
      which is non-optimized by a complementary radiotherapy and negative exeresis margins.&#xD;
&#xD;
      Currently, there is no intraoperative technique to better visualize the tumor limits in real&#xD;
      time. With fluorescence techniques, an accurate mapping of tumor extension can be considered.&#xD;
      Recently, Atallah et al. (2015) demonstrated the use of fluorescence during a head and neck&#xD;
      surgery in mice, as a tool allowing for better surgical margins. Digonnet et al (2015) found&#xD;
      a tumor fragment after an injection of indocyanine green (ICG) intravenously in salvage&#xD;
      surgery for patient with head and neck cancer.&#xD;
&#xD;
      The ability of ICG to detect a surgical margin positive intraoperatively has never be&#xD;
      evaluated in irradiated area.&#xD;
&#xD;
      The aim of this pilot study is to evaluate the interest of fluorescence in salvage surgery&#xD;
      for recurrence of head and neck cancer in irradiated area.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2016</start_date>
  <completion_date type="Actual">September 6, 2017</completion_date>
  <primary_completion_date type="Actual">August 10, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of indocyanine green labeling in Irradiated Area</measure>
    <time_frame>1 day</time_frame>
    <description>The indocyanine green labeling in irradiated areas will be compared to the histological result on the surgical specimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of indocyanine green labeling on surgical margins</measure>
    <time_frame>1 day</time_frame>
    <description>The indocyanine green labeling on surgical margins will be compared to the surgical margins histological result</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>eligible patient for a salvage surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green</intervention_name>
    <description>intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.</description>
    <arm_group_label>eligible patient for a salvage surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old&#xD;
&#xD;
          -  Head and Neck Squamous Cell Carcinoma confirmed by biopsy&#xD;
&#xD;
          -  Non metastatic disease&#xD;
&#xD;
          -  Resectable tumour&#xD;
&#xD;
          -  Locoregional recurrence or new localization in pre irradiated territory at a dose ≥ 50&#xD;
             Gy with or without chemotherapy&#xD;
&#xD;
          -  Haematological constants, liver function and kidney function adapted in the 15 days&#xD;
             before inclusion:&#xD;
&#xD;
               -  Haemoglobin ≥ 9 g / dL&#xD;
&#xD;
               -  Polymorphonuclear neutrophils ≥ 1.5 x 10 9&#xD;
&#xD;
               -  Platelet ≥ 100 x 109 / L&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  ALT and AST &lt;3 times ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
               -  Serum creatinine &lt;110 mmol / L or creatinine clearance&gt; 55 ml / min (method of&#xD;
                  Cockcroft)&#xD;
&#xD;
               -  Absence of proteinuria&#xD;
&#xD;
          -  WHO 0 or 1&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Patient affiliated to the social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient considered as non eligible for a salvage surgery&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Hypersensitivity to indocyanine green or allergy to seafood or reaction to iodinated&#xD;
             contrast agents&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CORTESE Sophie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cortese S, Kerrien E, Yakavets I, Meilender R, Mastronicola R, Renard S, Leroux A, Bezdetnaya L, Dolivet G. ICG-induced NIR fluorescence mapping in patients with head &amp; neck tumors after the previous radiotherapy. Photodiagnosis Photodyn Ther. 2020 Sep;31:101838. doi: 10.1016/j.pdpdt.2020.101838. Epub 2020 May 30.</citation>
    <PMID>32479902</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Indocyanine Green</keyword>
  <keyword>Salvage surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

